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Abstract
In recent years members of the tripartite motif-containing (TRIM) family of E3 ubiquitin ligases have been shown to both
positively and negatively regulate viral defence and as such are emerging as compelling targets for modulating the anti-viral
immune response. In this study we identify TRIM68, a close homologue of TRIM21, as a novel regulator of Toll-like receptor
(TLR)- and RIG-I-like receptor (RLR)-driven type I IFN production. Proteomic analysis of TRIM68-containing complexes
identified TRK-fused gene (TFG) as a potential TRIM68 target. Overexpression of TRIM68 and TFG confirmed their ability to
associate, with TLR3 stimulation appearing to enhance the interaction. TFG is a known activator of NF-kB via its ability to
interact with inhibitor of NF-kB kinase subunit gamma (IKK-c) and TRAF family member-associated NF-kB activator (TANK).
Our data identifies a novel role for TFG as a positive regulator of type I IFN production and suggests that TRIM68 targets TFG
for lysosomal degradation, thus turning off TFG-mediated IFN-b production. Knockdown of TRIM68 in primary human
monocytes resulted in enhanced levels of type I IFN and TFG following poly(I:C) treatment. Thus TRIM68 targets TFG, a novel
regulator of IFN production, and in doing so turns off and limits type I IFN production in response to anti-viral detection
systems.
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Introduction
Innate immune receptors play key roles in viral recognition and
activation of transcription factors important for driving both type I
IFN and pro-inflammatory cytokine production. Production of
type I IFN (IFN-a and IFN-b) following viral and bacterial
infection is a critical step in the innate immune response. Whilst
important for both anti-viral and anti-bacterial immunity, IFNs
and pro-inflammatory cytokines can become pathogenic when
overproduced, resulting in inflammatory autoimmune diseases
such as systemic lupus erythematosus (SLE) or Crohn’s disease.
Thus, proteins that function to turn off and limit the production of
such cytokines are important immunoregulatory factors. Members
of the tripartite motif-containing (TRIM) family of E3 ubiquitin
ligases have been shown to both positively [1–6] and negatively
[7–13] regulate immune responses, mainly by ubiquitinating key
signalling intermediates and thus either enhancing their activity or
targeting them for ubiquitin-mediated degradation, respectively.
Viral recognition, broadly speaking, results in activation of
pathways regulating the activity of either NF-kB or interferon
regulatory factor (IRF) 3 or IRF7. Anti-viral sensors principally
detect viral nucleic acid, and under pathogenic circumstances can
detect RNA and DNA released from damaged host cells. They
include the Toll-like receptors (TLRs), TLR3, 7 and 9, which are
endosomally located and the cytosolic RNA-sensing RIG-like
helicase receptors (RLRs). RIG-I and melanoma differentiation-
associated protein 5 (MDA-5) have been shown to recognise viral
RNA whereas multiple DNA-receptors exist (reviewed in [14,15]).
Once activated these PRRs recruit adaptor proteins, such as TIR
domain-containing adaptor protein inducing interferon-b (TRIF)
and myeloid differentiation primary response gene 88 (MyD88) to
the TLRs and mitochondrial anti-viral signalling protein (MAVS)
to the RLRs, which facilitate the formation of signalling complexes
that result ultimately in the activation of downstream kinases such
as IkB kinases and TANK-binding kinase 1 (TBK1). Together
these regulate the activity of the transcription factors NF-kB and
the IRF family members (IRF3 and 7) and the subsequent
production of pro-inflammatory cytokines and type I IFNs
(reviewed in [16]).
Recently a role for TRIMs in anti-viral immunity has been
highlighted (reviewed in [17]). TRIM proteins act as either
positive or negative regulators of type I IFN production, utilising
their E3 ligase activity for activation (via K63-linked polyubiqui-
tination) or degradation (via K48-linked polyubiquitination) of key
signalling molecules on viral recognition pathways. Structurally,
the TRIM protein family are characterised by the presence of a
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RING finger domain, one or two B-box domains and a coiled-coil
domain in their N-terminal region [18]. The most common C-
terminal domain expressed by TRIMs is the SPRY domain (also
known as a B30.2 domain), a domain known to regulate anti-viral
immune responses [19]. TRIM21 was first described as a target for
autoantibody production in SLE and Sjo¨gren’s syndrome (SS)
[20–22] and was amongst the first of the TRIM proteins shown to
negatively regulate IFN production [7,23]. As a negative regulator,
TRIM21 targets the IRF family members IRF3 and IRF7 for
degradation [7,8]. However, a positive role for TRIM21 in driving
pro-inflammatory cytokine production has also been demonstrat-
ed, underlining the complex role this protein plays in innate
immune responses [24–26]. TRIM68 is most structurally and
phylogenetically similar to TRIM21, with both TRIMs expressing
a PRY/SPRY domain in their C-terminal region [27]. Little is
known regarding a role for TRIM68 in regulating innate immune
signalling, however it has been shown to be significantly
upregulated in prostate cancer cells [28,29] and has also been
shown to cross react with melanoma inhibitor of apoptosis protein
(ML-IAP)-specific cytotoxic T cells isolated from melanoma
patients [30]. Although TRIM68 has been identified as a cellular
target for autoantibody responses in SS and SLE [31], whether it
has any role in immune responses remain unknown.
Our findings indicate a hitherto unsuspected role for TRIM68
as a negative regulator of type I IFN production. In this respect,
we identify TRK-fused gene (TFG) as TRIM68’s target, a protein
known to interact with the scaffold proteins inhibitor of NF-kB
kinase subunit gamma (IKK-c) and TRAF family member-
associated NF-kB activator (TANK), thus positively facilitating
NF-kB activation and pro-inflammatory cytokine production [32].
In this study we identify a positive role for TFG in driving IFN-b
production, with knockdown of TFG significantly inhibiting
TRIF-driven IFN-b induction. We demonstrate that TRIM68
binds and polyubiquitinates TFG, leading to its lysosomal
degradation and hence inhibition of TFG-dependent signalling.
We show that TRIM68 knockdown in human monocytes results in
an increase in IFN-b and TFG levels post TLR3 stimulation,
further validating the negative role TRIM68 exerts on these
responses. This is the first report that demonstrates a role for TFG
as a positive regulator of type I IFN production and a role for
TRIM68 as a negative regulator of this process.
Materials and Methods
Ethics Statement
In the case of human blood collection for monocyte isolation,
participants provided their written informed consent to participate
in this study. All samples were collected with informed consent and
used in strict accordance with ethical approval from Royal College
of Surgeons in Ireland research ethics committee REC269.
Cell culture
Human embryonic kidney (HEK) 293T cells (Unitech Ltd) and
HeLa cells (ATCC) were cultured in DMEM medium (Biosera)
supplemented with 10% FCS (Biosera), penicillin and streptomy-
cin (100 mg/ml) (Biosera). Human PBMCs were isolated from
whole blood by density gradient centrifugation using Ficoll-Paque
Plus (GE Healthcare). Human monocytes were subsequently
extracted from PBMCs by positive selection using CD14 beads
(Miltenyi Biotec) and cultured in RPMI-1640 medium (Biosera)
supplemented with 10% FCS and penicillin–streptomycin
(100 mg/ml). Following stimulation, supernatants were collected
and RANTES levels determined by ELISA (R&D Systems)
according to the manufacturer’s recommendations.
Plasmids and reagents
FLAG-TRIM68 was a kind gift from Dr. Shigetsugu Hata-
keyama, (Hokkaido University Graduate School of Medicine,
Sapporo, Japan). FLAG-TRIF, FLAG-TBK1, FLAG-IRF3,
FLAG-RIG-I, FLAG-MAVS and the IFN-b luciferase reporter
construct were kind gifts from Prof. Katherine Fitzgerald
(University of Massachusetts Medical School, Worcester, MA,
USA). The kB-luciferase reporter construct was a kind gift from
Dr. R Hofmeister (University of Regensburg, Germany). MYC-
MyD88 construct was a kind gift from Dr. Aisling Dunne (Trinity
College Dublin, Ireland). HA-Ubiquitin was a kind gift from Dr.
Andrew Bowie (Trinity College Dublin, Ireland). GFP-TRIM68
construct was a kind gift from Dr. David Rhodes (Cambridge
Institute for Medical Research, UK). MYC-TFG was a kind gift
from Dr. Angela Greco (The Foundation of the Carlo Besta
Neurological Institute, Italy). Ligands used were 59ppp-dsRNA
and polyinosinic:polycytidylic acid (poly(I:C)) (Invivogen). shRNAs
used were human TRIM68 shRNA and human TFG shRNA
(Sigma). Primary antibodies used were anti-alpha actinin, anti-HA
(Santa Cruz Biotechnologies), anti-FLAG (Sigma), anti-TFG and
anti-MYC (Abcam).
Luciferase reporter gene assays
HEK293T or HeLa cells were seeded at 26105/ml and
transiently transfected for 18–24 hr with 40 ng of the indicated
reporter constructs, increasing amounts of a TRIM68/TFG
construct (10 ng, 50 ng and 100 ng) and an appropriate driver
construct (50 ng). In the case of TFG shRNA work, HEK293T
cells were transiently transfected with 40 ng of p125 and 250 ng of
shRNA (Scrambled or TFG) and 24 hr later with 50 ng of TRIF.
All transfections were performed using Metafectene (Biontex)
according to the manufacturer’s recommendations. Luciferase
activity was standardised to renilla luciferase plasmid activity to
normalise for transfection efficiency.
Confocal microscopy
HeLa cells were transfected with 2 mg of GFP-TRIM68 for 18–
24 hr and were then treated with poly(I:C) (20 mg/ml) for 6 or
24 hr. Cells were fixed with methanol/acetone (Sigma) at a 1:1
ratio, stained with an anti-TFG antibody and mounted in DAPI
containing mounting media (Dako). Localisation of TFG was
visualised using an Alexa fluor 546 conjugated anti-rabbit
secondary antibody (Molecular Probes) and cells were imaged by
confocal microscopy on a Zeiss LSM 510 META (Oberkochen,
Germany).
Western blot and immunoprecipitation analysis
For immunoprecipitation experiments, HEK293T cells were
seeded at 56105/ml, in 10 ml, in 10 cm dishes and transfected
with a total of 4 mg of plasmid for 18–24 hr. Cells were lysed on
ice in radioimmunoprecipitation lysis buffer (16PBS, 1% Nonidet
P-40, 0.5% Na-deoxycholate, 0.1% SDS, 1 mM KF, 1 mM
Na3VO4, 10 mg/ml leupeptin, and 1 mM PMSF) followed by
immunoprecipitation with either anti-FLAG (M2), anti-TFG or
anti-HA (Y-11/12CA5) pre-coupled to protein-G Sepharose beads
(Sigma). In some cases HEK293T cells were treated with the
lysosomal inhibitor NH4Cl (20 mM) for 18 hr as indicated or with
the proteosomal inhibitor MG132 (10 mM) (Sigma) for 2 hr.
Trypsin digest and MS/MS analysis
10% acrylamide gels were stained using Pierce Silver Staining
Kit (Thermo Scientific) as per manufacturers’ instructions. Gel
pieces were excised, destained and digested in sequencing grade
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modified trypsin (Promega) (20 ng/ml). The resulting peptide
mixtures were resuspended in 0.1% formic acid and analysed by
nanoelectrospray liquid chromatography mass spectrometry
(Nano-LC MS/MS). Spectra were searched using the SEQUEST
algorithm against the International Protein Index (IPI) database
(http://www.ebi.ac.uk/IPI/IPIhelp.html).
Real-time PCR
Total RNA was extracted from cell cultures using an RNeasy kit
(Qiagen) and reverse transcribed to cDNA using Omniscript
reverse transcriptase (Qiagen) according to manufacturer’s
recommendations. Quantitative real-time PCR was performed
using SYBR Green Taq ReadyMix (Sigma) on an Applied
Biosystems 7500 real-time PCR machine and the data was
normalised to an 18S RNA reference. IFN-b, TRIM68 and 18S
RNA templates were amplified using primers (sequences available
on request) with an annealing temperature of 56uC. Real-time
PCR data was analysed using the 22DDCt method [33].
Cloning of TRIM68 PRY/SPRY
Briefly, the 780 bp TRIM68 PRY/SPRY region was amplified
by PCR from genomic DNA. The primers used were as follows:
foward 59 atgttgcaggatattcag -39 and reverse 59 – gtcctccccatc-
caggga -39. The foward and reverse primers created Not1 and
HindIII sites, respectively, and the PCR products were ligated into
these sites in the pCDNA3.1/myc-His(-) vector. Transformants
were validated by sequencing (MWG Eurofins Genetics, Ebers-
berg, Germany).
Microparticle manufacture and TRIM68 shRNA
knockdown
Poly (lactic-co-glycolic acid) (PLGA) 503 (Boehringer Ingelheim)
microparticles containing either scrambled (Scr) or TRIM68
shRNA (Sigma) were prepared using a double emulsion solvent
evaporation method. Lyophilised microparticles were sized using a
Malvern Mastersizer 2000 (Malvern Instruments) and the
encapsulation efficiency determined using a Quant-iT PicoGreen
assay (Invitrogen). Fluorescence was detected at 485 nm excitation
and 535 nm emission wavelengths using the Victor Wallac
Multiplate Reader. Human monocytes were plated at 26106/ml
and treated with microparticles containing 150 ng of shRNA (Scr
or TRIM68) dissolved in 150 ml of serum free RPMI-1640
medium for 48 hr. 24 hr post microparticle addition, cells were
treated with poly(I:C) (20 mg/ml) for the remaining 24 hr before
real-time PCR analysis or western blotting was performed.
Statistical analysis
All data are presented as the average of three separate
experiments 6 standard error of the mean (S.E.M). Statistical
significance for reporter gene assays was determined using a two-
way ANOVA analysis followed by a Bonferroni post test in which
everything was compared back to the 0 ng data set. For all other
comparisons, the two-tailed Student t-test was used. Data were
deemed to be significantly different at p value ,0.05 (*) (**p,
0.01, ***p,0.001). GraphPad Prism 5.0 software was used to test
for statistical significance.
Results
TRIM68 is a novel negative regulator of TLR/RLR-driven
IFN-b promoter activity
Both TRIM21 and TRIM68 have previously been identified as
targets for autoantibody production in SLE [34,35]. In addition to
this, bioinformatic analysis indicates that TRIM68 is the most
closely related TRIM family member to TRIM21, with both
TRIMs clustering together in 66% of replicate trees [27]. TRIM21
and TRIM68 are also located in close proximity to each other
within a cluster of TRIMs on chromosome 11 at positions p15.4
and p15.5, respectively (27). Like TRIM21 and the other proteins
found in this cluster (with the exception of TRIM3), TRIM68
contains a SPRY/PRY domain, a domain which has been shown
to be important in immune regulation (reviewed in [36]). T-Coffee
alignment of the amino acid sequence of both TRIM members
generated a sequence similarity score of 98% (Figure 1A), whereas
a Clustal W alignment indicates that TRIM68 and TRIM21 share
a total of 43.16% sequence identity (Figure S1), suggesting that
TRIM68 may have split from TRIM21 via gene duplication. To
determine whether TRIM68 also functions as a negative regulator
of type I IFN responses similar to TRIM21, we assessed its ability
to affect IFN-b promoter activity. The addition of increasing
amounts of a plasmid expressing TRIM68 significantly inhibited
poly(I:C)-, TRIF- and TBK1-driven IFN-b promoter activity but
had no effect on IRF3-driven IFN-b promoter activity (Figure 1B).
To determine the potential role of TRIM68 on RIG-I-driven IFN-
b promoter activity, cells were transiently transfected with RIG-I
ligand dsRNA, RIG-I and its adaptor protein MAVS, and
increasing amounts of TRIM68 (Figure 1C). As with TRIF-driven
IFN-b promoter activity, TRIM68 negatively regulated dsRNA,
RIG-I- and MAVS-driven reporter gene activation (Figure 1C).
RANTES levels were also significantly decreased in cells in which
TRIM68 was overexpressed post poly(I:C) and dsRNA treatment,
suggesting TRIM68 negatively regulates TLR3- and RLR-driven
RANTES release (Figure 1D). Collectively our results indicate a
novel negative regulatory role for TRIM68 downstream of both
TLR- and RLR-driven IFN-b production and suggest the target
for TRIM68 lies downstream of TBK1 but upstream of IRF3.
Interestingly TRIM68 also negatively regulated NF-kB promoter
activity downstream of MyD88, TRIF and TBK1 suggesting that
it works at a point of crosstalk between pathways controlling both
type IFN production and NF-kB activation or alternatively
suggesting that TRIM68 may have two different targets on IRF
versus NF-kB pathways (Figure S2).
TRIM68 interacts with TRK fused gene (TFG), a novel
regulator of IFN-b production
Having demonstrated that TRIM68 inhibited both TLR- and
RLR-driven type I IFN production, we next sought to identify
potential targets for TRIM68. To do this, FLAG-TRIM68-
containing immunocomplexes were separated by SDS PAGE,
silver-stained and bands which were present in the FLAG-
TRIM68 immunoprecipitated lane but not in the IgG control
lane were excised and analysed by Nano-LC MS/MS (Figure 2A,
Figure S3). TFG was identified as a potential target of TRIM68
and the ability of the two proteins to interact confirmed following
overexpression of FLAG-tagged TRIM68 in HEK293T cells
followed by western blotting of TRIM68-containing complexes for
TFG (Figure 2B). The interaction between TRIM68 and TFG was
greatly enhanced following 24 hr poly(I:C) stimulation, with a
concomitant decrease in TFG levels also evident (Figure 2B). In
order to further validate the interaction between TRIM68 and
TFG, the immunoprecipitation was also carried out in reverse in
which TFG-containing complexes were immunoblotted for
TRIM68 with a resulting poly(I:C) inducible interaction between
TRIM68 and TFG again being evident (Figure 2C). Finally, the
interaction between TRIM68 and TFG was further confirmed by
confocal microscopy, with transiently transfected GFP-tagged
TRIM68 observed to interact with TFG following poly(I:C)
TRIM68 Regulates IFN-b Production by Degrading TFG
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treatment of HeLa cells for 24 hr (Figure 2D). Although in this
image TFG appears to be stabilized post poly(I:C) treatment,
quantification was carried out on multiple images using ‘‘ImageJ’’
software demonstrating that absolute TFG levels do in fact
decrease compared with unstimulated controls, thus supporting
the observation that TFG is degraded following poly(I:C)
stimulation (Figure 2D, lower figure).
TRIM68 polyubiquitinates TFG leading to its degradation
via its RING domain which also plays an important role in
TRIM68 negative inhibition on IFN-b production
Interestingly, we consistently observed reduced levels of TFG in
cell lysates in the presence of TRIM68 following stimulation
suggesting that TRIM68 may destabilise TFG. In keeping with
this, we observed a marked decrease in TFG protein levels in cells
co-expressing Ubiquitin, TFG, and TRIM68 even in the absence
of stimulation, indicating that TFG may be ubiquitinated and
hence targeted for degradation by TRIM68 (Figure 3A). In line
with this hypothesis, MYC-tagged TFG was shown to be
polyubiquitinated when co-expressed with both HA-tagged
ubiquitin and FLAG-tagged TRIM68 (Figure 3B). Analysis of
the nature of the polyubiquitin chains added on by TRIM68
proved to be inconclusive, suggesting that the TRIM68-mediated
polyubiquitination of TFG process is not entirely dependent on
either K48- or K63-linked ubiquitin chains and may involve
mixed K48/K63-linked chains or chains using alternative linkages
such as K29 (Figure S4). As ubiquitination can signal degradation
of target proteins via either proteasomal or lysosomal pathways
(reviewed in (37)), HEK293T cells overexpressing TFG, TRIM68
and Ubiquitin were treated with either the proteasome inhibitor,
MG132 (or DMSO vehicle control) or the lysosomal degradation
inhibitor, NH4Cl (or PBS vehicle control) and the effect of
TRIM68 on TFG levels assessed by western blot analysis
(Figure 3C). Whilst proteosomal inhibition had no effect on
TFG degradation (Figure 3C, top panels), inhibition of lysosome-
phagosome fusion by NH4Cl resulted in a significant accumulation
of TFG in the presence of TRIM68 and Ubiquitin (Figure 3C,
bottom panels), suggesting that TFG is in fact being ubiquitinated
and degraded by TRIM68 via lysosomal degradative pathways.
TFG, a novel driver of type I IFN production, increases in
the absence of TRIM68
Given previous reports that TFG can positively influence pro-
inflammatory cytokine production, we next set out to elucidate if
TFG had any effect on type I IFN production. Transient
transfection of HEK293T cells with increasing amounts of TFG
lead to IFN-b promoter activation (Figure 4A). In addition, TFG
knockdown in the same cells resulted in decreased TRIF-driven
IFN-b promoter activity, indicating that TFG is indeed a positive
regulator of IFN-b production in this system (Figure 4B). In
contrast, overexpression of TFG in HeLa cells resulted in a
significant increase in RANTES release both before and 24 hr
after poly(I:C) stimulation further suggesting TFG functions as a
positive regulator of the type I IFN response (Figure 4C). Having
shown that TFG positively influences IFN-b production and
TRIM68 promotes ubiquitination and degradation of TFG, we
next set out to determine whether this ubiquitination was involved
in the inhibition of IFN-b signalling. The activity of most E3
ligases, like TRIM68, is specified by a RING (Really Interesting
New Gene) Finger domain. In order to investigate whether this
Figure 1. TRIM68 is structurally similar to TRIM21 and down-regulates type I IFN production downstream of TBK1. (A) Human TRIM68
and TRIM21 amino acid sequence alignment using T-Coffee (http://tcoffee.crg.cat/apps/tcoffee/do:regular). An * (asterisk) indicates positions which
have a single, fully conserved residue. A: (colon) indicates conservation between groups of strongly similar properties - scoring .0.5 in the Gonnet
PAM 250 matrix. A. (period) indicates conservation between groups of weakly similar properties - scoring ,0.5 in the Gonnet PAM 250 matrix. (B–C)
HeLa cells were transfected with 40 ng full-length IFN-b promoter, empty vector (EV) control and increasing amounts of TRIM68 as indicated for 18 hr
and were then stimulated with 20 mg/ml poly(I:C) for 24 hr. In all other cases HEK293T cells were transfected with 40 ng full-length IFN-b promoter
and were co-transfected with 50 ng of the relevant promoter drivers TRIF, TBK1, IRF3 (B), or dsRNA, RIG-I, MAVS (C) as well as with empty vector (EV)
control and increasing amounts of TRIM68 as indicated. Cells were assayed for relative fold increase of reporter gene activity 18–24 hr post-
transfection. (D) HeLa cells were transiently transfected with 1 mg of TRIM68 together with 1 mg/ml 59ppp-dsRNA for 6 and 24 hr or 18 hr later with
20 mg/ml poly(I:C) for 6 and 24 hr before supernatants were collected for RANTES ELISA. In all cases presented data is graphed from the average of
three separate experiments 6 S.E.M. *p,0.05 was considered significant.
doi:10.1371/journal.pone.0101503.g001
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domain played a role in how TRIM68 negatively regulated TFG-,
TBK1- and dsRNA-driven IFN-b promoter activity, a mutant
TRIM68 plasmid was cloned lacking the RING domain (TRIM68
PRY/SPRY) and cells were transiently transfected with TFG,
TBK1 or dsRNA and increasing amounts of the mutant TRIM68
plasmid and % inhibition on IFN-b promoter activity was
Figure 2. TRIM68 interaction with TRK-fused gene protein (TFG) increases post TLR3 stimulation. (A) TRIM68 bound proteins were
immunoprecipitated from lysates with anti-FLAG coated agarose beads (Sigma). Immunoprecipitation using normal mouse IgG functioned as a
negative control. Selected bands were excised, trypsin digested and analysed by mass spectrometry. A western blot showing corresponding lysates
from the silver stained gel was immunoblotted for FLAG to verify successful transfection and immunoprecipitation of FLAG-TRIM68. Immunoblots
shown are from a single experiment and are representative of two independent experiments. (B) HEK293T cells were transfected with 2 mg of EV and
FLAG-TRIM68. TRIM68 containing complexes were immunoprecipitated using anti-FLAG coated beads and blotted for TFG and FLAG. Lysates were
immunoblotted for TFG and FLAG. Immunoblots shown are from a single experiment and are representative of three independent experiments. (C)
HEK293T cells were transfected with 2 mg of EV and FLAG-TRIM68. TFG containing complexes were immunoprecipitated using anti-TFG coated beads
and immunoblotted for FLAG and TFG. Lysates were immunoblotted for TFG and FLAG. Immunoblots shown are from a single experiment and are
representative of three independent experiments. (D) HeLa cells were transfected with 2 mg of GFP-TRIM68 (green) expression plasmid and
stimulated with 20 mg/ml of poly(I:C) for 6 and 24 hr. Cells were fixed and then stained with anti-TFG before mounting in DAPI in order to visualise
nuclei (blue). Images were taken under oil immersion at 63X magnification. Panels on the right contain zoomed images of white box in previous
panel. Images shown are from a single experiment and are representative of three independent experiments. The raw integrated density value (sum
of pixel values) was calculated using ImageJ software (1.48 4-bit Java) for TFG only images for each poly(I:C) time point. Presented data is graphed
from the average of sixteen separate images 6 S.E.M. *p,0.05 was considered significant.
doi:10.1371/journal.pone.0101503.g002
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Figure 3. TRIM68 negatively regulates type I IFN production via polyubiquitination and lysosomal degradation of TFG. (A) HEK293T
cells were co-transfected with MYC-TFG, HA-Ubiquitin, FLAG-TRIM68 and EV. Lysates were immunoblotted for TFG, alpha actinin, HA and FLAG.
Immunoblots shown are from a single experiment and are representative of three independent experiments. (B) HEK293T cells were transfected with
1 mg of EV, MYC-TFG, HA-Ubiquitin and FLAG-TRIM68. Ubiquitin containing complexes were immunoprecipitated using anti-HA coated beads and
immunoblotted for MYC, FLAG and HA. Lysates were immunoblotted for FLAG and HA. Immunoblots shown are from a single experiment and are
representative of three independent experiments. (C) Cells were treated with proteasomal inhibitor MG132 (10 mM) and DMSO vehicle control for
2 hr or lysosomal inhibitor NH4Cl (20 mM) or PBS vehicle control for 18 hr before cells were lysed and immunblotted for MYC, alpha actinin, FLAG and
HA. In all cases the immunoblots shown are from a single experiment and are representative of three independent experiments. Densitometry data is
graphed from the average of three separate experiments 6 S.E.M. of TFG normalised to alpha actinin.
doi:10.1371/journal.pone.0101503.g003
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compared with full length TRIM68 (Figure 4D). The removal of
the RING domain significantly decreased TFG-, TBK1- and
dsRNA-driven inhibition on IFN-b promoter activity suggesting
that this domain plays an important role in how TRIM68 exerts its
negative effect on type I IFN production. The remaining
inhibition exhibited on IFN-b promoter in the absence of the
RING domain suggests that not all TRIM68 effects are RING
domain-dependent. The IFN-b promoter has three principle
transcription factor binding sites; the PRD IV region which binds
the transcription factor ATF-2/c-Jun, the PRD III–I region which
binds the transcription factors IRF3 and IRF7 and the PRD II
region which binds NF-kB (Figure 4E). In order to investigate
which binding sites on the IFN-b promoter TRIM68 could
negatively regulate, we carried out TFG-driven reporter gene
assays on the full length IFN-b promoter as well as each of the
three segments (Figure 4E). In keeping with TFG being a target for
TRIM68, the addition of increasing concentrations of a plasmid
expressing TRIM68 significantly inhibited TFG-driven full length
IFN-b promoter activity as well as TFG-driven PRD II and PRD
III-I promoter activity whilst having no effect on TFG-driven
PRD IV promoter activity (Figure 4F). Having shown that
TRIM68 targets TFG for degradation in vitro, we next assessed
the effects of TRIM68 knockdown on both IFN-b and TFG levels.
Human monocytes were transfected with either scrambled (Scr)
control shRNA or shRNA targeted against TRIM68 and
knockdown efficiency determined by assessing TRIM68 mRNA
levels (Figure 4G). A significant increase in both IFN-b mRNA
levels and TFG protein levels before and after 24 hr poly(I:C)
stimulation was evident in TRIM68 deficient monocytes
(Figure 4H and 4I) with densitometric analysis shown on the
right) consistent with TRIM68 negatively regulating type I IFN
production via degradation of TFG. Thus, TRIM68, via inducing
the degradation of TFG targets both NF-kB and IRF3/7 activity
downstream of PRRs in order to turn off and limit the production
of type I IFNs.
Discussion
The critical role that negative regulators play in TLR- and
RLR-induced responses and in guarding against the onset of
autoimmune and inflammatory diseases is demonstrated by the
development of spontaneous disease in mice lacking these proteins
such as TRIM21 and TIR8/SIGGIR [23,37,38]. Although at
present there is broad recognition for the involvement of TRIMs
in certain biological processes including cancer, retroviral restric-
tion and autoimmunity [27,39,40], only recently has a real
appreciation arisen for the specific and crucial role that TRIMs
play as regulators of innate immune pathways [41,42]. SPRY
domain-containing TRIMs are thought to have multiple roles as
anti-viral factors [43]. Whilst many of them, such as TRIM5a,
have been shown to have direct anti-viral properties [44], others
such as TRIM21, have been demonstrated to regulate type I IFN
production in order to presumably prevent the overproduction of
these potentially pathogenic cytokines [7,8]. Thus, the negative
effects of TRIM68 on IFN production observed are in keeping
with this theory.
During this study we observed that TRIM68 is a potent
negative regulator of type I IFN production, downstream of both
TLR and RLR pathways. Results from reporter gene assays
implied that TRIM68 was exerting its effect on type I IFN
production downstream of TBK1. Proteomic analysis identified
TFG as a bona fide TRIM68 target, a novel regulator of IFN-b
induction, and hence an ideal target for TRIM68 in this respect.
Most of the literature surrounding TFG demonstrates an
involvement of this protein in cancer, with only two studies
suggesting it plays a role in immune regulation [32,45]. Regarding
its role in cancer, TFG has been found to be preferentially up-
regulated in prostate cancer cell lines and tissues, with TFG
expression being associated with a higher probability of tumour
recurrence following surgery [46]. In addition TFG has been
identified as a putative metastatic melanoma tumour suppressor
gene [47] and is also thought to play a role in non-small cell lung
cancer, acting as a translocation partner for anaplastic lymphoma
kinase (ALK) [48]. Miranda et al were the first to suggest TFG may
play a role in immune regulation, showing that TFG over-
expression can enhance the effect of TNF-a, TANK, TRAF2 and
TRAF6 in inducing NF-kB activity suggesting that TFG is part of
a complex containing TANK and IKK-c [32]. We demonstrate
for the first time that TFG can drive IFN-b promoter activity, an
effect that is down-regulated in the presence of TRIM68,
potentially via its effects on NF-kB as reported by Miranda et al.
In fact, TBK1, although mostly appreciated for its role in IRF3
activation, has also been shown to play an important role in
regulating NF-kB activity [49], [50]. Our results suggest that
TRIM68 degrades TFG at a point of pathway convergence in
which downstream events lead to the activation of both NF-kB
and IRF3.
Recently it has become evident that a significant level of
crosstalk exists between TRIF-driven and MyD88-driven path-
ways. For example TBK1 and IKKe have been shown to be
activated by TLR ligands that signal via MyD88 and the canonical
IKKs and the IKK-related kinases are thought to have several
substrates in common in addition to their unique physiological
substrates, such as IkBa and IRF3 [51,52]. It is therefore possible
that TFG may be part of the TBK1/IKKe/TANK/IKKc
signalosome complex, first identified by Chariot et al [53], and
the degradation of TFG by TRIM68-mediated ubiquitination
results in the disruption of this complex and subsequent inhibitory
effect on type I IFN production. Although we could not establish
the exact lysine residues involved in TRIM68 ubiquitination of
TFG, it is possible that both K48 and K63 ubiquitin linkages play
a part as both lysines have recently been shown to signal lysosomal
degradation [54]. Interestingly, a recent study has suggested that
TFG binds TRIM25 upon viral infection and negatively regulates
RIG-I-mediated type I IFN signalling [45]. In contrast, we
observed no inhibitory effects of TFG on IFN-b production,
instead our results indicate a role for TFG in promoting IFN-b
production.
Interestingly, both TRIM68 and TRIM21 are known autoan-
tigens in SLE and primary Sjo¨grens syndrome (pSS), both
autoimmune diseases associated with a high level of circulating
type I IFN and an IFN-stimulated gene (ISG) signature [20,31].
Whilst a number of recent studies have linked TRIM21 with the
pathogenesis of SLE [23,55], to date no known role for TRIM68
in regulating IFN production or potential involvement in SLE or
pSS has been demonstrated [35,56]. Interestingly however, a
recent report has shown the TRIM68 gene to be downregulated in
pSS [57], potentially, given our results, resulting in a loss of
negative regulation of type I IFN production and contributing to
the enhanced levels of IFNs and ISG signature observed in pSS.
An analysis of the role of TRIM68 and potentially TFG in pSS
and SLE is therefore warranted.
In this study we demonstrate TRIM68 as a potent negative
regulator of type I IFN production via degradation of the
activatory protein TFG. We hypothesise therefore that a loss of
TRIM68 activity or downregulation of expression may contribute
to the overproduction of type I IFN typically observed in
inflammatory conditions such as SLE and pSS. While the
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molecular pathways underpinning these inflammatory disorders
are yet to be fully elucidated, modulation of TRIM68 activity may
hold some potential as a novel therapeutic target for the treatment
of disorders involving the overproduction of type I IFNs.
Supporting Information
Figure S1 T-Coffee alignment of human TRIM68 and TRIM21.
A clustal W alignment of TRIM68 and TRIM21 protein sequences.
(TIF)
Figure 4. TRIM68 knockdown results in an increase in IFN-b and TFG levels post TLR3 stimulation. (A) HEK293T cells were transfected
with 40 ng full-length IFN-b promoter and increasing amounts of TFG as indicated. Cells were assayed for relative fold increase of reporter gene
activity 18–24 hr post-transfection. (B) HEK293T cells were transfected with 400 ng full-length IFN-b promoter and were co-transfected with 250 ng
of Scrambled (Scr) or TFG shRNA as indicated and 24 hr later 50 ng of TRIF. Cells were assayed for relative fold increase of reporter gene activity 18–
24 hr post-transfection. Presented data is graphed from one experiment. (C) HeLa cells were transiently transfected with 1 mg of TFG and 18 hr later
were stimulated with 20 mg/ml poly(I:C) for 24 hr before supernatants were collected for RANTES ELISA. (D) HEK293T cells were transfected with
40 ng full-length IFN-b promoter and were co-transfected with 50 ng of TFG, TBK1 or dsRNA as well as with empty vector (EV) control and 50 ng of
full length TRIM68 or TRIM68 mutant lacking the RING and B-box domain (TRIM PRY/SPRY) as indicated. Cells were assayed for relative fold increase of
reporter gene activity 18–24 hr post-transfection and % inhibition on promoter activity was calculated. Presented data is graphed from the average
of three separate experiments 6 S.E.M. *p,0.05 was considered significant. (E) A schematic of the IFN-b promoter which consists of three principle
transcription factor binding sites, the PRD IV region which binds the transcription factor ATF-2/c-Jun, the PRD III–I region which binds the
transcription factors IRF3 and IRF7 and the PRD II region which binds NF-kB. (F) HEK293T cells were transfected with 40 ng full-length IFN-b promoter
or the PRD segments (PRD II, PRD III-I, PRD IV) and 50 ng of TFG as well as with EV control and increasing amounts of TRIM68 as indicated. Cells were
assayed for relative fold increase of reporter gene activity 18–24 hr post-transfection. (G–I) Human monocytes were treated with PLGA microparticles
containing either Scrambled (Scr) or TRIM68 shRNA for 48 hr. Real-time PCR was used to measure TRIM68 mRNA levels post treatment (G). After
treatment with PLGA microparticles, monocytes were stimulated with poly(I:C) for 24 hr before IFN-b mRNA was measured (H). Human monocytes
which have been treated with shRNA containing microparticles as above were immunoblotted for TFG and alpha actinin. Immunoblots shown are
from a single experiment and are representative of three independent experiments (I). In all other cases, presented data is graphed from the average
of three separate experiments 6 S.E.M. *p,0.05 was considered significant.
doi:10.1371/journal.pone.0101503.g004
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Figure S2 TRIM68 negatively regulates NF-kB promoter
activity. HEK293T cells were transfected with 40 ng full-length
kB-luciferase reporter construct and 50 ng of the relevant
promoter drivers MyD88, TRIF and TBK1 as well as with EV
control and increasing amounts of TRIM68 as indicated. Cells
were assayed for relative fold increase of reporter gene activity 18–
24 hr post-transfection. Presented data is graphed from the
average of three separate experiments 6 S.E.M. *p,0.05 was
considered significant.
(TIF)
Figure S3 TRIM68 potential interacting protein peptides were
determined using Nano-LC MS/MS. A table of potential
TRIM68 interacting proteins identified from excised gel fragment
using MS/MS analysis. This list is compiled of peptide hits from
two individual experiments. The ‘‘Global Proteome Machine
(GPM)’’ http://www.thegpm.org/ and ‘‘Mascot’’ http://www.
matrixscience.com/ home search engines were used to identify
proteins from mass spectrometry data. The list includes protein
name with swiss prot identifier (sp), the molecular weight of the
protein in Daltons (Da), the pro peptide score, the cross correlation
(XC) score and the sequence coverage percentage.
(TIF)
Figure S4 Lysines 48 and 63 are two possible lysines involved in
TRIM68-mediated polyubiquitination of TFG. HEK293T cells were
co-transfected with MYC-TFG, FLAG-TRIM68, wildtype HA-
Ubiquitin, or ubiquitin mutants (HA-Ubiquitin K48R, HA-Ubiquitin
K63R) for 18–24 hr. Ubiquitinated proteins were immunoprecipi-
tated from lysates using anti-HA coated agarose beads and possible
ubiquitination of TFG was assessed by immunoblotting with anti-
MYC. Immunoblots shown are from a single experiment and are
representative of two independent experiments.
(TIF)
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